Pari Mody counsels clients on legislative, regulatory, and legal matters related to healthcare and US Food and Drug Administration regulated products, including pharmaceuticals, medical devices, foods, dietary supplements, and cosmetics.

Ms. Mody represents a wide range of clients, including manufacturers, healthcare systems, trade associations, and nonprofit research foundations, on issues related to healthcare reform, Medicare coverage and reimbursement, Medicaid, health information technology, federal research funding, and the marketing of FDA-regulated products. She has experience navigating the legislative and regulatory processes, drafting legislative language, preparing comment letters, and developing and implementing legislative and regulatory strategies for individual clients and coalitions.

Ms. Mody frequently works with both congressional and agency-level staff to advocate on behalf of clients. She has worked on significant healthcare legislation, including the 21st Century Cures Act, FDA Reauthorization Act of 2017, SUPPORT for Patients and Communities Act, and COVID-19 stimulus legislation.

Prior to joining the firm, Ms. Mody was an associate at another international law firm and worked as a researcher at the Johns Hopkins University and the University of Pennsylvania.

Experience

  • Pharmaceutical manufacturers in Congressional investigations and oversight hearings related to pricing, patents, and innovation.
  • Provider of in-home testing services in blocking a nearly 70 percent payment reduction for in-home EEG services through an integrated legislative and regulatory strategy, including direct advocacy and coalition building.
  • Medical device manufacturer in securing Medicare coverage for the client's device, following a multi-year, coordinated congressional and agency effort.
  • Manufacturer of FDA-regulated consumer products in challenges before the National Advertising Division of the Advertising Self-Regulatory Council.
  • Retailer of cosmetic and personal care products regarding product safety and managing Congressional inquiries.
  • Healthcare systems in securing enactment of legislative reforms that support coordination of care provided to medically complex children.
  • Two pro bono research and patient advocacy foundations in securing the introduction of bicameral, bipartisan legislation to authorize increased federal funding for research dedicated to a specific disease.

Perspectives

HEROES IN THE HOUSE: Congress Begins Consideration of a 5th COVID-19 Response Package Totaling $3 Trillion in New Spending
Coronavirus: Legislative & Public Policy Advisory
The Over-the-Counter Monograph Safety, Innovation, and Reform Act Is Enacted: Top Five Takeaways for Manufacturers of OTC Drug Products
Advisory
Telehealth During COVID-19: New Rules And Considerations
Commercial Contracts Law360, Compliance Law360, Consumer Protection Law360, Cybersecurity & Privacy Law360, Health Law360, Life Sciences Law360, Personal Injury & Medical Malpractice Law360, Public Policy Law360, Technology Law360, Telecommunications Law360
Policy Developments Related to the Coronavirus Pandemic Part II: The CARES Act
Coronavirus: Legislative and Public Policy Webinar
Coronavirus Legislative Update: The CARES Act Becomes Law
Coronavirus: Legislative and Public Policy Advisory
More

Recognition

Best Lawyers
"Ones to Watch"–Health Care Law (2021)
Excellence in Advocacy Awards
Finalist, Excellence in a Federal Issue Campaign (2017)

Credentials

Education
  • JD, University of Maryland Francis King Carey School of Law, 2014, magna cum laude, Order of the Coif
  • BA, Oberlin College, 2006, high honors
Admissions
  • District of Columbia
  • Maryland
Activities
  • Member, American Health Lawyers Association
  • Member, Women in Government Relations
Overview

Email Disclaimer